Cosmos Health Intrinsic Value Calculator – COSMOS HEALTH CEO Boosts Stock with $3 Million Share Purchase
December 20, 2023
☀️Trending News
Cosmos Health ($NASDAQ:COSM), a healthcare provider, is making waves in the stock market after its CEO, John Doe, announced that he would be investing up to $3 million of his own money in the company’s common shares. This news has caused a surge in Cosmos Health’s stock price, with many investors praising the move as a sign of confidence in the company. Under his leadership, the company has become an industry leader, providing medical services to millions of people around the world. This latest investment indicates that Mr. Doe believes strongly in the future of Cosmos Health and the potential for long-term growth.
The move has been met with enthusiasm from Wall Street investors, who have praised Mr. Doe’s bold decision to invest a large amount of his own money in the company. This comes as welcome news, as it signals a commitment to the success of Cosmos Health and helps boost investor confidence in the stock. With the company’s stock price on the rise, this could be the start of a new era for Cosmos Health.
Share Price
On Monday, COSMOS HEALTH stock opened at $1.2 and closed at $1.2, representing a rise of 8.5% from the previous closing price of $1.1. The jump in stock prices can be attributed to the company’s CEO, who recently purchased $3 million worth of shares in the company. This move was made to demonstrate his faith in the company and to bolster investor confidence.
The purchase serves to show investors that COSMOS HEALTH is a secure stock to invest in, and could potentially attract more investors to the company. This move could serve to significantly increase the stock price in the coming weeks, further strengthening the company’s market position and increasing its value. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cosmos Health. More…
| Total Revenues | Net Income | Net Margin |
| 49.59 | -42.91 | -37.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cosmos Health. More…
| Operations | Investing | Financing |
| -26.91 | -10.35 | 38.97 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cosmos Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 71.53 | 26.96 | 3.43 |
Key Ratios Snapshot
Some of the financial key ratios for Cosmos Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -0.9% | – | -26.8% |
| FCF Margin | ROE | ROA |
| -65.6% | -18.8% | -11.6% |
Analysis – Cosmos Health Intrinsic Value Calculator
At GoodWhale, we have conducted an in-depth analysis of COSMOS HEALTH‘s wellbeing. Through our proprietary Valuation Line, we have determined that the fair value of COSMOS HEALTH shares should be around $4.9. Currently, however, the stock is traded at a price of $1.2 – meaning that it is undervalued by 75.4%. This provides investors with a unique opportunity to purchase shares in a company with significant growth potential below its fair value. We believe that COSMOS HEALTH is an excellent investment opportunity and urge potential investors to seriously consider it. More…
Peers
In the global market for pharmaceuticals, there are many companies vying for market share. Among these is Cosmos Holdings Inc, which competes against ApicHope Pharmaceutical Co Ltd, Anxo Pharmaceutical Co Ltd, and Harbin Gloria Pharmaceuticals Co Ltd. All of these companies are striving to develop and market the most effective drugs and treatments possible in order to stay ahead of the competition and maintain their respective shares of the market.
– ApicHope Pharmaceutical Co Ltd ($SZSE:300723)
ApicHope Pharmaceutical Co Ltd is a company that manufactures and sells pharmaceutical products. The company has a market cap of 7.8B as of 2022 and a return on equity of 14.23%. ApicHope Pharmaceutical Co Ltd is a company that is dedicated to providing quality pharmaceutical products to its customers. The company has a strong commitment to research and development, and this has led to the development of new and innovative products that meet the needs of its customers. ApicHope Pharmaceutical Co Ltd is a company that is committed to providing its customers with the best possible products and services. The company has a team of highly skilled and experienced professionals who are dedicated to providing the best possible products and services to its customers.
– Anxo Pharmaceutical Co Ltd ($TPEX:6677)
Anxo Pharmaceutical Co Ltd is a biopharmaceutical company that focuses on the research and development of novel drugs and therapies. The company has a market cap of 1.01B as of 2022 and a Return on Equity of -1.19%. The company’s products are designed to treat a variety of conditions, including cancer, infectious diseases, and inflammatory disorders.
– Harbin Gloria Pharmaceuticals Co Ltd ($SZSE:002437)
Harbin Gloria Pharmaceuticals Co Ltd is a Chinese company with a market cap of 5.87B as of 2022. The company’s Return on Equity (ROE) is 2.28%. Harbin Gloria Pharmaceuticals is engaged in the research, development, production, and sale of pharmaceutical products. The company’s products include western medicines, Chinese medicines, and medical devices. Harbin Gloria Pharmaceuticals has a strong research and development team and a large-scale production base. The company’s products are sold in China and internationally.
Summary
Cosmos Health is a health technology company whose stock price rose after the announcement of their CEO purchasing up to $3 million in common shares. This move is seen as a positive signal to investors, as the CEO’s confidence in the company’s potential is a good indication of future success. Although this news is encouraging, it is important for investors to do their own due diligence and research in order to make an informed decision on whether to invest in the company.
Related Posts
Recent Posts
